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Hyperlipidemia: A risk factor for chronic allograft dysfunction. have the same impact on CAD. The risk is increased in
While the early results of renal transplantation have improved severe, late, or recurrent episodes [6, 7], and is affected
in the last years, but the long-term allograft survival have not by the HLA system, especially in cases with HLA-DRimproved to the same extent. The major cause of these graft
locus mismatches [6]. In the same way, it has been sug-losses is chronic allograft dysfunction (CAD). The pathogene-
gested that the utilization of low-maintenance doses ofsis of CAD is complex and results from a interaction of immune
and nonimmune factors. Between these non-immunological immunosuppressants, especially cyclosporine A (CsA),
related factors there are two cardiovascular risk factors, hyper- can lead to a state of sub-optimal immunosuppression
tension and especially hyperlipidemia, that have been impli- that forms an additional risk factor for CAD [8].cated in the development and progression of CAD. Lipid pro-
Nonimmune factors may be involved in CAD patho-file abnormalities are very prevalent in renal transplant
genesis related to a diminished functional mass of thepatients. In last years several authors have reported an associa-
tion between different lipid profile alterations and CAD. We renal graft. This diminution can be caused by dispropor-
conducted an observational study in our group to determine tionate size differences between donor and receptor, and
the relationship between different lipid disturbances and CAD.
by differences in donor age, gender, and ethnicity. InThe hypertriglyceridemia and the Lp(a)30 mg/dL before and
addition, structural and functional damage produced byafter transplantation were, between the lipid abnormalities, the
two independent risk factors for CAD in a multivarite analysis. prolonged graft ischemia, surgical manipulation, and de-
layed graft function, that is the clinical manifestation of
ischemia–reperfusion injury could contribute also. The
With the introduction of new immunosuppressive decrease in nephron number could lead to hyperfiltration
drugs, the early results of renal transplantation have in remnant nephrons, leading to progressive renal failure
dramatically improved. However, these have not been [9]. Other factors, such as prolonged immunosuppressant
paralleled by a similar improvement in long-term allo- toxicity (especially for CsA and Tacrolimus), and cardio-
graft survival. The number of functioning grafts declines vascular risk factors such as hypertension and especially
after the first year, and, excluding cases of death with hyperlipidemia, could contribute to renal injury and the
functioning grafts, the major cause of these graft losses appearance of CAD. Because one of the hallmarks of
is chronic allograft dysfunction (CAD) [1, 2]. CAD is a vascular lesion characterized by intimal prolif-
CAD has been defined as a progressive functional eration and luminal narrowing that resembles the athero-
deterioration of the transplanted kidney in the absence sclerotic disease, many investigators have proposed a
of other causes of graft disease [3]. The clinical diagnosis role for cardiovascular risk factors in the pathogenesis
of CAD is suggested by slowly rising plasma creatinine and progression of CAD. Hypertension after trans-
concentrations, increasing proteinuria, and worsening plantation has indeed been linked with CAD [10] when
hypertension [4]. A histological classification of the se- it is also present before transplantation [11].
verity of CAD, called the Banff classification, has been
formulated [5].
ROLE OF LIPID ABNORMALITIES INThe pathogenesis of CAD is complex and only par-
CHRONIC ALLOGRAFT DYSFUNCTIONtially understood, and has been considered to result from
an interaction of various immune (sometimes historically Renal insufficiency is often accompanied by hyperlip-
called “chronic rejection”) and nonimmune factors im- idemia, which worsens in severity as one approaches
plicated in its development and progression. For the ESRD. After successful renal transplantation, however,
immune factors, there is acute rejection, but not all forms there is no assurance of the remission of dyslipidemia.
Indeed, lipid profile changes and hyperlipidemia are
found in 16% to 72% of patients, depending on the timeKey words: renal transplantation, graft loss, lipid profile, hypertriglyc-
eridemia. serum lipids are examined after transplantation, and by
which factors they are influenced [12]. Lipid abnormali- 2002 by the International Society of Nephrology
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ties in transplanted patients have been associated with of the adhesion molecules ICAM 1 and ELAM 1. These
activated macrophages are present in chronically re-multiple factors: age, pretransplant serum lipids [13, 14],
body weight [15], allograft dysfunction [13], hyperinsu- jected allografts and express TGF- receptors. Oxidized
LDL is the ligand for scavenger receptors on macro-linemia and diabetes [16], antihypertensive therapy [16],
prednisone dosage [16], and cyclosporine dosage and phages, which are then converted into foam cells. It also
increases the expression of PDGF receptors in smoothblood levels [17].
The renal transplant population frequently displays muscle cells that can be converted to fibroblast-like cells
with a matrix-producing capacity [25]. On the otherelevations in total cholesterol, LDL cholesterol, triglyc-
erides, apolipoprotein B (Apo B), and lipoprotein(a) or hand, a diminution in nitric oxide production has also
been reported [12]. All these effects lead to the fibrosisLp(a). There may also be diminution in HDL, and qual-
itative alterations in lipoproteins such as the increased of the intimal vessels that is characteristic of CAD.
Coagulation abnormalities have also been related tosusceptibility of LDL to oxidation. Thus, the lipid profile
in renal transplant patients may show an atherogenic CAD. These include impaired fibrinolysis with increased
PAI-1 levels, the synthesis of which is related in a dose-pattern linked with the appearance of the cardiovascular
complications that are the most frequent causes of death dependent way to oxidized LDL levels [12]. Elevated
levels of fibrinogen have also been described [26, 27].in this population [18]. In this setting, it is important
to note that vascular lesions in systemic atherosclerosis Several reports have pointed toward a link between
different lipid profile alterations and CAD.share similarities with lesions seen in CAD. Macro-
phages, foam cells, lipoproteins, T cells, and proliferating
smooth muscle cells can be demonstrated in the vascular
TOTAL CHOLESTEROL AND
wall of kidneys with CAD lesions [18, 19]. These observa-
TRIGLYCERIDE LEVELS
tions have led to several studies on the role of lipid
Elevated cholesterol levels have been implicated in thedisorders in CAD. In animal models it has been demon-
aggravation of vascular lesions in experimental models ofstrated that a high cholesterol diet accelerates prolifera-
CAD [20]. Several clinical studies have also reportedtive vascular changes in graft vessels [20]. Although some
an association between cholesterol levels and differentreports have focused mainly on the role of elevation in
indicators of CAD.serum cholesterol, particularly on its quantitative abnor-
Dime´ny et al have reported that 42 patients with CADmalities, recent studies also show that there may be quali-
presented with higher cholesterol and triglyceride levelstative alterations to lipoproteins that can play a central
than did 42 controls without CAD at a similar time afterrole in the pathogenesis of CAD. An enrichment of
transplantation [28]. In another study by the same grouptriglycerides in VLDL and LDL lipoproteins has been
of 56 patients (28 with biopsy-proven CAD and 28 withreported in renal transplant patients. These small, dense
stable renal function), the pretransplant cholesterol lev-LDL particles with reduced receptor-specific uptake [21]
els were associated with a higher chronic damage scoreshow increased susceptibility to oxidative modification
and worse graft function at six months after transplanta-in the presence of inflammation when there is an excess
tion. There was also an association between increasedof production of reactive oxygen metabolites, as in allo-
cholesterol and triglyceride levels at six months and pa-grafts. Tanabe et al have demonstrated oxidized LDLs,
rameters indicating graft dysfunction at the same timeusing monoclonal antibodies in arteries of grafts of pa-
[13]. In both studies, however, patients with high choles-tients with hypercholesterolemia and with CAD [22]. It
terol levels had more frequent acute rejection episodes,has been reported that patients with CAD have in-
but no multivariate analysis was performed. In this con-creased levels of malondialdehyde, an end product of
text, it is difficult to differentiate the effects of hypercho-lipid peroxidation, and low levels of the antioxidants
lesterolemia alone. In another series of 151 patients, theyvitamin E and superoxide dismutase compared with pa-
found that high cholesterol levels before transplant andtients with stable graft function, and with controls [23].
at six months after transplantation were associated withThere is experimental evidence that oxidatively modi-
poor graft function at two years [29].fied LDL may be cytotoxic for mesangial cells and may
Wissing et al studied 772 renal transplant patients andalso have adverse effects on extracellular matrix compo-
reported that hypercholesterolemia was an independentnents [24]. The pathogenic mechanisms by which the
risk factor for kidney graft loss by chronic rejection inoxidized LDL could contribute to the development of
male patients with previous acute rejection [30]. RoodnatCAD are as follows. The oxidized LDL induces the acti-
et al agreed with this observation in a study carried outvation of T lymphocytes and the expression of adhesion
on 676 patients in whom cholesterol was an independentmolecules and class II MHC antigens. It also induces
predictor of graft outcome [31]. Sero´n and colleagueschemoattraction of monocytes and their differentiation
have published that the total serum cholesterol beforeinto macrophages, and enhances their adhesion to the
endothelial surface, probably by inducing the expression transplantation was the only predictor of CAD with
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Table 2. Association between the studied parameters and the riskTable 1. Association between the studied parameters and the risk
of developing CAD, using multiple logistic regression analysis: of developing CAD, using multiple logistic regression analysis:
General characteristics and lipid metabolism after transplantationGeneral characteristics and lipid metabolism before transplant
Factor OR 95% CI P value Factor OR 95% CI P value
Age 0.81 (0.70–0.93) 0.004Age 0.89 (0.83–0.98) 0.006
Gender Gender
Male 1 (0.02–1.98) 0.182Male 1 (0.17–3.07) 0.680
Female 0.74 Female 0.23
DiabetesDiabetes
No 1 (0.98–2.95) 0.477 No 1 (0.01–4.41) 0.368
Yes 0.28Yes 0.53
HDL Acute rejection
No 1 (0.07–30.03) 0.79445 mg/dL 1 (0.04–0.73) 0.017
45 mg/dL 0.17 Yes 1.49
HDL, 1 yearLp(a)
30 mg/dL 1 (1.19–1.83) 0.013 45 mg/dL 1 (0.01–0.22) 0.006
45 mg/dL 0.1030 mg/dL 1.40
Triglycerides Lp(a), 1 year
30 mg/dL 1 (1.17–1.65) 0.015200 mg/dL 1 (1.05–1.98) 0.048
200 mg/dL 1.27 30 mg/dL 1.50
Cholesterol, 6 monthsVLDL
25 mg/dL 1 (1.00–1.22) 0.034 240 mg/dL 1 (0.99–1.39) 0.057
240 mg/dL 1.2325 mg/dL 1.10
Triglycerides, 1 yearAbbreviations are: CAD, chronic allograft dysfunction; HDL, high density
200 mg/dL 1 (2.00–257.69) 0.011lipoprotein; Lp(a), lipoprotein(a); VLDL, very low density lipoprotein; OR, odds
200 mg/dL 22.71ratio; CI, confidence interval.
Lipid-lowering therapy
No 1 (0.51–40.91) 0.221
Yes 4.13
CsA dosage, 2 years
transplant vasculopathy in 280 protocol biopsies at three 5 mg/kg 1 (0.09–0.57) 0.013
5 mg/kg 0.07months [32]. Isoniemi et al reported that patients with
a graft loss at four years after transplant had higher
cholesterol and triglyceride levels at two years following
transplant, but multivariate analysis failed to substantiate
ASSOCIATION BETWEEN HYPERLIPIDEMIAeither factor as predictors of graft outcome [33]. Fernan-
AND CAD: A SINGLE CENTER EXPERIENCEdez-Miranda et al have described the role of triglycerides
as independent risk factors for CAD in a case-controlled To determine the relationship between lipid distur-
bances and CAD, we conducted a study on 77 kidneystudy of 60 patients [27], as have Guijarro et al [34] and
Massy et al for 706 renal transplant patients [35]. How- transplant patients. All were transplanted in our unit dur-
ing a 14-month period, and we followed them from trans-ever, there are other studies that have failed to establish
any relationship between hyperlipidemia and CAD in plantation until four years later. The lipid profile was
determined before, at six months, and annually aftertwo series of 46 [36] and 450 patients[37], respectively.
transplantation until the end of the study. Other clinical
Lipoproteins and Lp(a) and biochemical variables were also studied at yearly
intervals. During the follow-up 19 patients were diag-Some reports have addressed the role of different lipo-
proteins in the development of CAD. Isoniemi et al nosed with CAD. Statistical analysis with multiple logis-
tic regression models were fitted to estimate the riskreported a positive correlation between LDL and CAD
[33]. Dime´ny et al reported a similar positive correlation (OR) of CAD associated with each variable.
Multivariate analysis shows that, between the pre-between LDL and VLDL with CAD, and also an inverse
correlation between HDL and indicators of chronic dam- transplant parameters, the independent risk factors for
CAD were: hypertriglyceridemia, VLDL25 mg/dL, andage [13, 29]. By contrast, Guijarro et al did not find any
correlation with the levels of LDL; however, HDL levels Lp(a)30 mg/dL (Table 1). The post-transplant parame-
ters that remained independent risk factors for CADbelow 35 mg/dl tended to be associated with an increased
risk of CAD [34]. Bosmans et al reported that an HDL were hypertriglyceridemia and Lp(a) 30 mg/dL at one
year. The presence of HDL 45 mg/dL at one year waslevel of less than 47 mg/dL was a risk factor for the func-
tional and morphological outcome of the graft at 18 related with a decreased risk of CAD. Between the gen-
eral parameters, the dosage of CsA 5 mg/kg at twomonths after transplant and was inversely associated with
the interstitial accumulation of oxidized LDL and conse- years and the patient age were also related with a de-
creased risk (Table 2). We failed to find any relationshipquently with the development of interstitial fibrosis [38].
The Lp(a) levels were not associated with CAD in the between cholesterol and CAD. Although this was sig-
nificant in univariate analysis, it lost significance in multi-report of Fernandez-Miranda et al [27].
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variate analysis, probably because of two strong pre- nal allograft survival and the degree of hypertension in
dictors: triglycerides and Lp(a). Our results agree with patients with CAD [7]. Angiotensin-converting enzyme
other reports and with Fernandez-Miranda et al [27] and (ACE) inhibitors have been suggested as therapeutic
Guijarro et al [34] on the role of triglycerides as an alternatives to treat post-transplant hypertension. Block-
independent risk factor for CAD. The last authors have ade of the rennin-angiotensin system with ACE inhibitors
also encountered an inverse relationship between HDL or angiotensin II receptor antagonists reduces urinary pro-
levels and CAD, but in their report the relationship tein excretion and protects against glomerulosclerosis.
was not independent of triglycerides as in our series of One short-term study found that lisinopril decreased pro-
patients. One of the most interesting findings is that tein excretion in transplant recipients in patients with hy-
the pretransplant lipid disturbances in triglycerides and pertension and proteinuria without adverse effects [41].
Lp(a) are risk factors for the appearance of CAD. These
observations could help indicate those patients at greater
LIPID-LOWERING AGENTSrisk for future graft dysfunction.
Drug treatment is necessary in many renal transplant
patients to control lipid disorders because dyslipidemia
THERAPEUTIC/PREVENTIVE APPROACHES is not particularly responsive to modifications in dietary
TO CAD fat intake. The HMG-CoA reductase inhibitors (statins)
The management of CAD remains one of the major are the most effective agents in reducing total lipids and
challenges facing transplant nephrologists. The approaches LDL cholesterol, and also the levels of oxidized LDL
to protect the allografted kidney in the long term include [18, 42]. In those few patients in whom hypertriglyceride-
immune and nonimmune interventions. mia and low HDL cholesterol are the leading lipid abnor-
malities, the fibric acid derivates, especially genfibrozil,
are the agents of choice. On the other hand, statins haveOPTIMIZING IMMUNOSUPPRESSIVE
direct effects on smooth muscle and mesangial cell prolif-STRATEGIES
eration and increase the synthesis of nitric oxide [42].
Current immunosuppressive regimens, though they Indeed, there is growing evidence that they could also
are very effective in controlling acute rejection, appear have immunosuppressive properties. A study of 97 heart
of limited value in CAD. There is no doubt that CsA has transplant patients treated with pravastatin showed re-
contributed to improvements for short-term and me- ductions in the degree of intimal hyperplasia in coronary
dium-term graft outcomes, but its impact on long-term arteries [43]. If the pathogenesis of allograft vascular
graft survival is more questionable in results obtained pathology in renal and cardiac transplant recipients is
from a large series [39]. Another new calcineurin inhibi- similar, then statins may also hold promise for preventing
tor, Tacrolimus, could have a potential benefit for long- or treating CAD, and there are ongoing studies on the
term graft survival. It is also possible that mycophenolate use of these drugs in renal transplant patients. Although
mofetil (MMF) can reduce the risk of CAD. There is ex- no conclusive data exist proving that statins directly in-
perimental evidence of this in rats. There is also experi- hibit the development of CAD, it is clear that at present
mental evidence in animal models that rapamycin, a new a therapeutic approach for CAD could be the combina-
immunosuppressant macrolide, could help prevent vascu- tion of lipid-lowering drugs and the selective use of anti-
lar disease, but this needs to be explored in clinical trials. hypertensive and immunosuppressive agents, which mi-
nor deleterious effects on lipoprotein metabolism.
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